How effective is Osimertinib?

Osimertinib (Osimertinib) is a targeted drug for non-small cell lung cancer with positive EGFR gene mutations. Its effect varies depending on individual differences. Osimertinib tablets have shown good efficacy in clinical trials, and can significantly extend the progression-free survival and overall survival of patients, while improving the quality of life of patients. In a study involving 275 patients who had not previously received an ALK inhibitor, it took an average of 24 months for patients treated with osimertinib to progress, compared with 11 months for those treated with crizotinib. When using osimertinib, patients need to follow their doctor's recommendations and undergo regular review and evaluation.